No Data
No Data
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE)
HC Wainwright & Co. Reiterates Buy on Allogene Therapeutics, Maintains $10 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Allogene Therapeutics with a Buy and maintains $10 price target.
Allogene Therapeutics Poised for Growth: A Strong Buy Rating Amidst Innovative Trials and Strategic Advancements
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript
Allogene Therapeutics' Stability Threatened by Banking Sector Turmoil
RBC Capital Reiterates Outperform on Allogene Therapeutics, Maintains $10 Price Target
RBC Capital analyst Luca Issi reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and maintains $10 price target.
No Data